SpringWorks Therapeutics Inc. [NASDAQ: SWTX] stock went on an upward path that rose over 7.63% on Friday, amounting to a one-week price increase of more than 8.94%. The company report on August 2, 2023 at 6:30 AM that SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights.
– Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment –.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
– Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors –.
Over the last 12 months, SWTX stock rose by 9.22%. The one-year SpringWorks Therapeutics Inc. stock forecast points to a potential upside of 39.55. The average equity rating for SWTX stock is currently 1.80, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.76 billion, with 62.46 million shares outstanding and 56.90 million shares in the current float. Compared to the average trading volume of 599.53K shares, SWTX stock reached a trading volume of 486266 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on SpringWorks Therapeutics Inc. [SWTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SWTX shares is $50.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SWTX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for SpringWorks Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 01, 2022.
The Average True Range (ATR) for SpringWorks Therapeutics Inc. is set at 1.61 The Price to Book ratio for the last quarter was 4.20, with the Price to Cash per share for the same quarter was set at 8.20.
SWTX Stock Performance Analysis:
SpringWorks Therapeutics Inc. [SWTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.94. With this latest performance, SWTX shares gained by 18.99% in over the last four-week period, additionally sinking by -1.46% over the last 6 months – not to mention a rise of 9.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SWTX stock in for the last two-week period is set at 61.68, with the RSI for the last a single of trading hit 67.18, and the three-weeks RSI is set at 58.47 for SpringWorks Therapeutics Inc. [SWTX]. The present Moving Average for the last 50 days of trading for this stock 27.78, while it was recorded at 28.62 for the last single week of trading, and 27.23 for the last 200 days.
Insight into SpringWorks Therapeutics Inc. Fundamentals:
Return on Total Capital for SWTX is now -56.87, given the latest momentum, and Return on Invested Capital for the company is -56.30. Return on Equity for this stock declined to -56.58, with Return on Assets sitting at -51.24. When it comes to the capital structure of this company, SpringWorks Therapeutics Inc. [SWTX] has a Total Debt to Total Equity ratio set at 0.94. Additionally, SWTX Total Debt to Total Capital is recorded at 0.93, with Total Debt to Total Assets ending up at 0.83. Long-Term Debt to Equity for the company is recorded at 0.85, with the Long-Term Debt to Total Capital now at 0.85.
Reflecting on the efficiency of the workforce at the company, SpringWorks Therapeutics Inc. [SWTX] managed to generate an average of -$1,222,101 per employee.SpringWorks Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.50 and a Current Ratio set at 11.50.
SpringWorks Therapeutics Inc. [SWTX] Institutonal Ownership Details
The top three institutional holders of SWTX stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in SWTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in SWTX stock with ownership which is approximately 5.7381%.
